febit’s HybSelect(TM) Technology Evaluated to Enable Targeting and Increase Speed for Next-Generation-Sequencing

LEXINGTON, Mass. and HEIDELBERG, Germany, Aug. 14 — febit

and the Translational Genomics Research Institute (TGen) today announced

the formation of a collaboration in which TGen will evaluate

Next-Generation-Sequencing equipment in conjunction with febit’s

proprietary Geniom(R) Microarray Technology.

febit’s HybSelect(TM) Technology enables selective DNA capture and

elution, an extremely efficient method to preselect sequences for

Next-Generation Sequencers. HybSelect is based on febit’s proven Geniom

Technology and uses arrays within microfludic biochips for the selection

process of targeted DNA. Geniom biochips are programmable and can contain

any desired set of capture probes. The new method combines the

extraordinary performance of latest sequencers with the efficient selection

capabilities of Geniom Technology.

“We are delighted to have TGen as our first U.S. pilot user of

HybSelect with the latest sequencing instrumentation,” said Cord F.

Staehler, president of febit. “We will obtain important data from TGen that

will help us as we prepare for the official introduction of HybSelect in

early 2009.” The collaboration provides TGen scientists pre-market access

to a highly developed DNA capturing method.

“There’s been a great deal of conversation on the future direction of

genomic research centers on next generation sequencing,” said Matthew

Huentelman, Ph.D., TGen associate investigator and lead collaborator on

this project. “This collaboration on the use and further development of

this method enhances the opportunities for TGen researchers to make a

difference in research utilizing next generation sequencing.”

TGen has been a user of the Geniom One device for the production and

microarray analysis of Geniom Biochips since 2006.

About febit

febit enables scientists to read, write and understand the code of

life: DNA. With its unique Geniom technology and services, febit is the

only company that puts the control of simplified genomic research in the

hand of the user. The seamless integration of DNA synthesis and analysis

and the superior support in experiment design and bioinformatics helps to

understand data and turn it into results. febit’s team of experienced

scientists is dedicated to support customers to solve the challenge of

understanding biological processes. Geniom is a technological and service

platform successfully implemented in basic and applied research by renowned

institutions and companies. Geniom exploits cutting-edge microarray

technology for analysis and synthesis of genes and genomes, providing

superior time- and cost-efficiency combined with an unsurpassed spectrum of

applications.

https://www.febit.com

About TGen

The Translational Genomics Research Institute (TGen) is a non-profit

501(c)(3) organization dedicated to conducting groundbreaking research with

life changing results. Research at TGen is focused on helping patients with

diseases such as cancer, neurological disorders and diabetes. TGen is on

the cutting edge of translational research where investigators are able to

unravel the genetic components of common and complex diseases. Working with

collaborators in the scientific and medical communities, TGen believes it

can make a substantial contribution to the efficiency and effectiveness of

the translational process. TGen’s vision is of a world where an

understanding of genomic variation can be rapidly translated in a manner

tailored to individual patients.